|1.||Maggi, C A: 9 articles (10/2008 - 01/2000)|
|2.||Fischer, A: 8 articles (05/2011 - 03/2001)|
|3.||Zimmer, Andreas: 7 articles (05/2013 - 11/2002)|
|4.||Marder, Eve: 7 articles (09/2008 - 03/2002)|
|5.||Vink, Robert: 6 articles (09/2015 - 06/2010)|
|6.||Dinh, Q T: 6 articles (05/2011 - 12/2004)|
|7.||Joos, G F: 6 articles (01/2005 - 04/2000)|
|8.||Beaudry, Francis: 5 articles (08/2015 - 12/2012)|
|9.||Darmani, Nissar A: 5 articles (04/2015 - 06/2008)|
|10.||Li, Lingjun: 5 articles (04/2009 - 09/2005)|
|1.||Asthma (Bronchial Asthma)
10/08/2010 - "The present study represents a preliminary step in elucidating the association between tachykinin gene polymorphisms and asthma susceptibility."
07/01/2001 - "This compound may be useful for future studies of tachykinin-related pathology such as asthma."
07/01/1992 - "Data from several studies suggest that tachykinins may play an important role in the pathophysiology of airway diseases, especially asthma. "
06/01/2004 - "The role of the tachykinin NK1 receptor in airway changes in a mouse model of allergic asthma."
08/29/2003 - "In conclusion, distal from mast cell activation, the tachykinin NK1 receptor is crucial for the infiltration of pulmonary neutrophils and the development of tracheal hyperreactivity in non-atopic asthma."
01/01/1999 - "Together, the data of the present study suggest that tachykinin-mediated rat paw edema depends on the activation of NK1, NK2 and NK3 receptor subtypes, with apparent major involvement of NK1 receptors subtypes."
01/01/1999 - "Receptor subtypes involved in tachykinin-mediated edema formation."
08/01/1999 - "The tachykinins were inactive in knockout mice, but compound 48/80 induced a significantly greater edema (P < 0.05) than that observed in paired wild-type mice. "
08/01/1999 - "Furthermore, results suggest that edema induced by the tachykinins, although totally dependent on NK(1) receptor-mediated mechanism, contains a mast cell-dependent component. "
08/01/1999 - "The mechanisms involved in tachykinin-induced neurokinin-1 (NK(1)) receptor-mediated edema formation have been studied in anesthetized wild-type and NK(1) knockout mice. "
08/01/1997 - "Others studies have also indicated that tachykinin NK1-receptors are involved in immediate or delayed neurogenic inflammation including microvascular leakage and the subsequent increase in plasma protein extravasation. "
12/01/1998 - "Airway neurogenic inflammation is caused by tachykinins released from peripheral nerve endings of sensory neurons within the airways, and is characterized by plasma protein extravasation, airway smooth muscle contraction and increased secretion of mucus. "
04/01/1997 - "Neurogenic inflammation is mediated by release of tachykinins from sensory nerves, which stimulate plasma extravasation from postcapillary venules. "
01/01/1995 - "In humans, tachykinins have been shown to increase plasma exudation in the nasal mucosa, but whether neurogenic inflammation also occurs in the lower airways still remains to be proven."
01/01/1995 - "In the peripheral nervous system, tachykinins released from peripheral endings of sensory nerves are responsible for the neurogenic inflammation phenomenon. "
10/01/1999 - "Results of early clinical trials with tachykinin neurokinin NK1 receptor antagonists demonstrate enhanced control of acute emesis with their addition to currently available agents and promising activity in controlling delayed emesis. "
06/01/2009 - "These data demonstrate that there is both a major central nervous system component and a minor peripheral nervous system component to tachykinin-mediated vomiting. "
08/17/1998 - "Tachykinin NK1 receptor antagonists injected into the medulla oblongata are known to abolish vomiting induced by vagal afferent stimulation. "
06/30/1999 - "Recent clinical trials in man showed that tachykinin NK1 receptor antagonists are effective in treating depression and chemotherapy-induced emesis. "
06/01/2003 - "The antiemetic effect of recently developed tachykinin NK-1 (NK-1)-receptor antagonists has been shown to be additive to that of existing treatments for acute and chronic symptoms, especially chronic nausea/vomiting. "
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
06/01/2003 - "Peripheral tachykinins (TKs) are believed to play a role in the pathogenesis of inflammatory bowel diseases (IBD). "
01/01/2003 - "Tachykinins have been implicated in inflammatory responses such as those occurring in inflammatory bowel disease. "
05/01/1988 - "To test this hypothesis in a human inflammatory disease, quantitative receptor autoradiography was used to examine possible abnormalities in tachykinin binding sites in surgical specimens from patients with inflammatory bowel disease. "
06/15/2001 - "Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation."
06/01/1988 - "These data, together with our studies on surgical specimens from patients with inflammatory bowel disease, suggest that in a pathophysiological state tachykinins and their receptors may play a role in inflammatory bowel disease and should permit a rational approach to designing neuropeptide antagonists which may prove effective in treating inflammatory diseases."
|1.||Neurokinin-2 Receptors (Neurokinin 2 Receptor)
|4.||Serotonin (5 Hydroxytryptamine)
|5.||Messenger RNA (mRNA)
|9.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|10.||CRF receptor type 1
|1.||Drug Therapy (Chemotherapy)